Optimization of PEEP During Laparoscopic Surgery

Sponsor
Karaganda Medical University (Other)
Overall Status
Recruiting
CT.gov ID
NCT05222893
Collaborator
I.M. Sechenov First Moscow State Medical University (Other)
96
1
2
14.4
6.7

Study Details

Study Description

Brief Summary

Lung-protective ventilation (LPV) during general anesthesia can trigger the development of early postoperative pulmonary complication (PPC) and ventilator associated lung injury. One of the proven components of the LPV is low tidal volume (TV). Data on the positive end-expiratory pressure (PEEP) parameters adjustment in laparoscopic surgery, as well as the effects on the respiratory biomechanics, lung tissue and respiratory muscles damage are limited and not clear.

The objective of the study is to evaluate the ability of the esophageal pressure (Pes) based controlled personalized PEEP adjustment, to improve the biomechanics of the respiratory system and oxygenation due to laparoscopic cholecystectomy.

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: Respiratory monitoring
  • Diagnostic Test: Capnography
  • Diagnostic Test: Arterial blood gas
  • Device: Esophageal pressure
N/A

Detailed Description

During laparoscopic surgery pressure on alveoli increases, due to in the conditions of pneumoperitoneum, muscle relaxation, the patient's position on the operating table, excess body weight and other factors. As the consequence, the alveoli collapse due to negative transpulmonary pressure. The personalized PEEP adjustment for each particular patient during laparoscopic surgery can help to avoid the adverse effects on biomechanical parameters of the respiratory system, the early PPC incidence and improve overall patients' recovery.

The objective of the study is to evaluate the ability of the esophageal pressure (Pes) based controlled personalized PEEP adjustment, to improve the biomechanics of the respiratory system and oxygenation due to laparoscopic cholecystectomy.

Investigators will measure if PEEP adjustment according to the pressure indicators in the lower third of the esophagus Pes (intervention group) versus PEEP constantly set at 5 cmH2O (control group) gives better outcomes and prevent the early PPC incidence in hospitals.

After the induction, intubation and insertion of the esophageal balloon catheter, TV for patients both groups is set to 6 ml / kg BMI: for men (50+0.91* (height-152.4), for women (45+0.91* (height-152.4); minute ventilation (MV) to ensure the level of PetCO2 - 30-35 mmHg, respiratory rate (RR) 15-25/min (maximum up to 35/min).

Gas exchange parameters including partial pressures of oxygen (PaO2) and carbon dioxide (PaCO2) in arterial blood will be measured before the induction (T0), after 1 hour after surgery (T5) and after 24 hours after surgery (T6), then will calculate PAO2/FiO2 respectively.

FiO2, oxygen saturation (SpO2), hemodynamic parameters including blood pressure (BP), heart rate (HR) will be recorded in all point of the study.

Following respiratory mechanics will be measured: plateau pressure (Pplat), PEEP, driving pressure (DP), Pes during inspiration and expiration, volumetric capnometry (VCO2), end-tidal carbon dioxide tension (PetCO2).

Respiratory system compliance (Cstat, Cl, Ccw), end-expiratory lung volume (EELV) will calculated after intubation (T1), after PEEP set according to the patient's group allocation PEEP Pes and PEEP 5 (T2), after initiating pneumoperitoneum (T3) and placing the patient in the reverse Trendelenburg position (T4).

This is a randomized controlled study in the operating room of the University hospitals.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
96 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Prevention
Official Title:
Optimization of Positive End-expiratory Pressure During Laparoscopic Surgery
Actual Study Start Date :
Apr 14, 2021
Anticipated Primary Completion Date :
Mar 29, 2022
Anticipated Study Completion Date :
Jun 26, 2022

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: PEEP Pes

PEEP adjustment according to the pressure indicators in the lower third of the esophagus Pes (intervention group)

Diagnostic Test: Respiratory monitoring
Measurement of the plateau pressure, positive end-expiratory pressure, driving pressure, end-expiratory lung volume, compliance of respiratory system on volume-controlled ventilation

Diagnostic Test: Capnography
Measurement of end-tidal carbon dioxide tension, volume of CO2 eliminated per minute

Diagnostic Test: Arterial blood gas
Measurement of the oxygen partial pressure and the carbon dioxide partial pressure

Device: Esophageal pressure
Measurement the pressure in the lower third of esophagus during inspiration and expiration

Active Comparator: PEEP 5

PEEP constantly set at 5 cmH2O (control group)

Diagnostic Test: Respiratory monitoring
Measurement of the plateau pressure, positive end-expiratory pressure, driving pressure, end-expiratory lung volume, compliance of respiratory system on volume-controlled ventilation

Diagnostic Test: Capnography
Measurement of end-tidal carbon dioxide tension, volume of CO2 eliminated per minute

Diagnostic Test: Arterial blood gas
Measurement of the oxygen partial pressure and the carbon dioxide partial pressure

Device: Esophageal pressure
Measurement the pressure in the lower third of esophagus during inspiration and expiration

Outcome Measures

Primary Outcome Measures

  1. Change in arterial partial oxygen tension to inspiratory oxygen fraction (PaO2/FiO2) ratio [5 minutes before intubation,1 hour after surgery, 24 hour after surgery]

    Calculation of the arterial partial oxygen tension to inspiratory oxygen fraction (PaO2/FiO2) ratio using arterial oxygen tension measurement and compare between groups

Secondary Outcome Measures

  1. Dynamics of the end-expiratory lung volume [5 minutes after induction and intubation, 5 minutes after PEEP setting, 5 minutes after pneumoperitoneum, 5 minutes after reverse Trendelenburg position]

    Calculation the end-expiratory lung volume (ml) and compare with expected and between groups

  2. Dynamics of the respiratory biomechanics [5 minutes after induction and intubation, 5 minutes after PEEP setting, 5 minutes after pneumoperitoneum, 5 minutes after reverse Trendelenburg position]

    Calculation the compliance of respiratory system (ml/mbar) and compare between groups at all time points

  3. Dynamics of the volume of CO2 eliminated per minute [5 minutes after induction and intubation, 5 minutes after PEEP setting, 5 minutes after pneumoperitoneum, 5 minutes after reverse Trendelenburg position]

    Measurement of volume of CO2 eliminated per minute (VCO2 in ml/min), than compare the trends as a marker of lung ventilation

  4. Dynamics of the partial pressure of CO2 in exhaled gas [5 minutes after induction and intubation, 5 minutes after PEEP setting, 5 minutes after pneumoperitoneum, 5 minutes after reverse Trendelenburg position]

    Measurement of partial pressure of CO2 in exhaled gas (PetCO2 in mmHg) than compare the trends as a marker of lung ventilation

  5. Dynamics of the hemodynamic parameters [5 minutes after induction and intubation, 5 minutes after PEEP setting, 5 minutes after pneumoperitoneum, 5 minutes after reverse Trendelenburg position]

    Measurement of the arterial blood pressure (mmHg) and compare between groups at all time points

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 65 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • patients with calculous cholecystitis American Society of Anesthesiologists Classification (ASA) I-II
Exclusion Criteria:
  • pregnancy

  • age less than 18 or more than 65 years

  • patients ASA III-IV

  • life-threatening heart rhythm abnormalities and/or systolic blood pressure < 80 mmHg despite norepinephrine at a dose > 2 μg/kg/min

  • primary lung diseases (e.g. interstitial lung diseases, lung emphysema) or tumour metastases in lungs

  • chronic decompensated diseases with extrapulmonary organ dysfunction (tumour progression, liver cirrhosis, congestive heart failure)

  • Glasgow coma score < 14

  • upper airways obstruction

Contacts and Locations

Locations

Site City State Country Postal Code
1 Karaganda Medical University clinical bases Karaganda Kazakhstan 100000

Sponsors and Collaborators

  • Karaganda Medical University
  • I.M. Sechenov First Moscow State Medical University

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Karaganda Medical University
ClinicalTrials.gov Identifier:
NCT05222893
Other Study ID Numbers:
  • PEEP-TPP
First Posted:
Feb 3, 2022
Last Update Posted:
Feb 3, 2022
Last Verified:
Dec 1, 2021
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
Yes
Product Manufactured in and Exported from the U.S.:
Yes
Keywords provided by Karaganda Medical University
Additional relevant MeSH terms:

Study Results

No Results Posted as of Feb 3, 2022